loading
Hims Hers Health Inc stock is traded at $28.07, with a volume of 10.98M. It is down -4.46% in the last 24 hours and up +0.25% over the past month. Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.
See More
Previous Close:
$29.38
Open:
$29.51
24h Volume:
10.98M
Relative Volume:
0.99
Market Cap:
$6.55B
Revenue:
$2.35B
Net Income/Loss:
$128.37M
P/E Ratio:
53.76
EPS:
0.5221
Net Cash Flow:
$57.42M
1W Performance:
-9.22%
1M Performance:
+0.25%
6M Performance:
+4.00%
1Y Performance:
-52.54%
1-Day Range:
Value
$27.53
$30.00
1-Week Range:
Value
$26.33
$31.79
52-Week Range:
Value
$13.74
$63.63

Hims Hers Health Inc Stock (HIMS) Company Profile

Name
Name
Hims Hers Health Inc
Name
Phone
415-851-0195
Name
Address
2269 CHESTNUT ST, SAN FRANCISCO
Name
Employee
2,442
Name
Twitter
Name
Next Earnings Date
2026-11-09
Name
Latest SEC Filings
Name
HIMS's Discussions on Twitter

Compare HIMS vs TAK, TEVA, HLN, ZTS, UTHR

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
HIMS icon
HIMS
Hims Hers Health Inc
28.07 6.55B 2.35B 128.37M 57.42M 0.5221
TAK icon
TAK
Takeda Pharmaceutical Co Adr
19.67 62.84B 29.91B 1.30B 3.49B 0.4056
TEVA icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
41.50 48.40B 17.53B 1.58B 444.18M 1.3457
HLN icon
HLN
Haleon Plc Adr
10.13 44.55B 14.54B 2.22B 2.58B 0.4871
ZTS icon
ZTS
Zoetis Inc
79.38 32.80B 9.51B 2.64B 2.14B 6.0361
UTHR icon
UTHR
United Therapeutics Corp
533.12 22.87B 3.17B 1.29B 1.01B 27.09

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date Action Analyst Rating Change
Sep-11-26 Resumed JP Morgan Neutral
May-12-26 Reiterated Needham Buy
Apr-24-26 Initiated JP Morgan Overweight
Mar-10-26 Upgrade BofA Securities Underperform → Neutral
Mar-10-26 Upgrade Citigroup Sell → Neutral
Mar-09-26 Upgrade Needham Hold → Buy
Feb-24-26 Downgrade BTIG Research Buy → Neutral
Jan-12-26 Initiated Evercore ISI In-line
Dec-09-25 Initiated Barclays Overweight
Oct-21-25 Initiated KeyBanc Capital Markets Sector Weight
Jun-23-25 Downgrade Needham Buy → Hold
Jun-04-25 Reiterated Needham Buy
Apr-29-25 Downgrade TD Cowen Buy → Hold
Feb-18-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-10-25 Downgrade Citigroup Neutral → Sell
Jan-07-25 Initiated BTIG Research Buy
Dec-17-24 Initiated Morgan Stanley Overweight
Nov-14-24 Downgrade BofA Securities Buy → Underperform
Aug-22-24 Initiated Needham Buy
Aug-09-24 Downgrade Imperial Capital Outperform → In-line
May-22-24 Downgrade Citigroup Buy → Neutral
Apr-16-24 Downgrade Jefferies Buy → Hold
Apr-10-24 Initiated Canaccord Genuity Buy
Feb-28-24 Upgrade Imperial Capital In-line → Outperform
Feb-26-24 Initiated Leerink Partners Market Perform
Dec-07-23 Initiated Imperial Capital In-line
Jul-28-23 Initiated TD Cowen Outperform
Apr-11-23 Initiated Robert W. Baird Neutral
Feb-09-23 Upgrade Jefferies Hold → Buy
Nov-08-22 Upgrade BofA Securities Neutral → Buy
Nov-08-22 Upgrade SVB Leerink Mkt Perform → Outperform
Oct-17-22 Downgrade Piper Sandler Overweight → Neutral
Sep-07-22 Initiated Truist Hold
Jul-15-22 Initiated SVB Leerink Underperform
Apr-14-22 Initiated Guggenheim Buy
Apr-01-22 Resumed Credit Suisse Outperform
Mar-10-22 Initiated Deutsche Bank Hold
Dec-02-21 Initiated Jefferies Hold
Nov-11-21 Upgrade Piper Sandler Neutral → Overweight
Jul-06-21 Initiated BofA Securities Neutral
May-20-21 Upgrade Credit Suisse Neutral → Outperform
Apr-21-21 Initiated Truist Hold
Mar-09-21 Initiated Credit Suisse Neutral
Mar-02-21 Upgrade Citigroup Neutral → Buy
Feb-17-21 Initiated Citigroup Neutral
Feb-12-21 Initiated Piper Sandler Neutral
Feb-08-21 Initiated Tigress Financial Buy
View All

Hims Hers Health Inc Stock (HIMS) Latest News

pulisher
Oct 16, 2026

Hims & Hers Health Inc (HIMS) Stock Down 4.5% -- Now Undervalued? GF Score: 75/100 - GuruFocus

Oct 16, 2026
pulisher
Oct 16, 2026

ROSEN, LEADING INVESTOR COUNSEL, Encourages Millrose Properties, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionMRP - GlobeNewswire Inc.

Oct 16, 2026
pulisher
Oct 16, 2026

HIMS DEADLINE: ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.

Oct 16, 2026
pulisher
Oct 16, 2026

What Does Hims & Hers Health (HIMS) Expansion Into The UK And Australia Mean? - Yahoo Finance

Oct 16, 2026
pulisher
Oct 16, 2026

Hims & Hers Health (HIMS) Alert: Securities Class Action Filed, Investors with Losses Encouraged to Contact Hagens Berman Before November 2, 2026 Lead Plaintiff Deadline - PR Newswire

Oct 16, 2026
pulisher
Oct 16, 2026

How Is Hims & Hers Health, Inc. (NYSE:HIMS) Reshaping Its Business? - Kalkine Media

Oct 16, 2026
pulisher
Oct 16, 2026

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Zacks Investment Research

Oct 16, 2026
pulisher
Oct 16, 2026

Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance

Oct 16, 2026
pulisher
Oct 15, 2026

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire Inc.

Oct 15, 2026
pulisher
Oct 15, 2026

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - The Killeen Daily Herald

Oct 15, 2026
pulisher
Oct 15, 2026

Kaplan Fox & Kilsheimer LLP Encourages Hims & Hers Health, Inc - The National Law Review

Oct 15, 2026
pulisher
Oct 15, 2026

Hims & Hers Health rises as HHS moves ahead with plan for compounding peptides - Seeking Alpha

Oct 15, 2026
pulisher
Oct 15, 2026

US FDA takes step to change peptide compounding policy - Reuters

Oct 15, 2026
pulisher
Oct 15, 2026

Hims & Hers Health Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire

Oct 15, 2026
pulisher
Oct 15, 2026

Our Commitment to Independent, Clinician-Led Care - Hims & Hers Newsroom

Oct 15, 2026
pulisher
Oct 15, 2026

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Oct 15, 2026
pulisher
Oct 15, 2026

INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP AnnouncesHIMS - GlobeNewswire Inc.

Oct 15, 2026
pulisher
Oct 14, 2026

Robbins LLP Reminds HIMS Investors of the Pending Class Action Lawsuit; Harmed Investors Should Contact the Firm for Information About Leading the Class Action - GlobeNewswire Inc.

Oct 14, 2026
pulisher
Oct 14, 2026

HIMS INVESTOR ALERT: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitNovember 2, 2026 Deadline - PR Newswire

Oct 14, 2026
pulisher
Oct 14, 2026

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Hims & Hers Health, Inc. (HIMS) Suffers a Larger Drop Than the General Market: Key Insights - Yahoo Finance

Oct 14, 2026
pulisher
Oct 14, 2026

Deadline Alert: Hims & Hers Health, Inc. (HIMS) Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP About Securities Fraud Lawsuit - GlobeNewswire Inc.

Oct 14, 2026
pulisher
Oct 14, 2026

Hims & Hers Expands Australian Women's Health Platform With Hers - Zacks Investment Research

Oct 14, 2026
pulisher
Oct 14, 2026

Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately - PR Newswire

Oct 14, 2026
pulisher
Oct 14, 2026

Innovating for Her - Hims & Hers Newsroom

Oct 14, 2026
pulisher
Oct 13, 2026

HIMS DEADLINE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.

Oct 13, 2026
pulisher
Oct 13, 2026

PZZA DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Papa John’s International, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionPZZA - GlobeNewswire Inc.

Oct 13, 2026
pulisher
Oct 13, 2026

Shareholders who lost money in shares of acquired Hims & Hers Health, Inc. (NYSE: HIMS) should contact Wolf Haldenstein Immediately - GlobeNewswire Inc.

Oct 13, 2026
pulisher
Oct 13, 2026

Lead Plaintiff Deadlines in Shareholder Class Action - GlobeNewswire

Oct 13, 2026
pulisher
Oct 13, 2026

Hims & Hers Health: The Bullish Case Is Hard To Forecast, But It Is Asymmetrical - Seeking Alpha

Oct 13, 2026
pulisher
Oct 12, 2026

Bronstein, Gewirtz & Grossman LLC Urges Hims & Hers Health, - GlobeNewswire

Oct 12, 2026
pulisher
Oct 12, 2026

Should You Trim Or Add To Your Hims & Hers Position Now? - Trefis

Oct 12, 2026
pulisher
Oct 12, 2026

Kaplan Fox Notifies Hims & Hers Health, Inc. (NYSE: HIMS) Investo - The National Law Review

Oct 12, 2026
pulisher
Oct 12, 2026

Hims & Hers Launches Hers Women’s-Health Platform in Australia - www.tokenpost.com

Oct 12, 2026
pulisher
Oct 12, 2026

Hers to Announce Third Quarter 2026 Financial Results on November 9, 2026 - HIMS investor relations

Oct 12, 2026
pulisher
Oct 12, 2026

Hims & Hers (HIMS) Launches Hers Brand in Australia, Expanding W - GuruFocus

Oct 12, 2026
pulisher
Oct 12, 2026

Hers Launches in Australia - Hims & Hers Newsroom

Oct 12, 2026
pulisher
Oct 12, 2026

Hers Launches in Australia, Built to Care for the Whole Woman - Business Wire

Oct 12, 2026
pulisher
Oct 12, 2026

HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with SBS Law - GlobeNewswire

Oct 12, 2026
pulisher
Oct 11, 2026

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.

Oct 11, 2026
pulisher
Oct 09, 2026

Hims & Hers Health, Inc. (HIMS) Stock Forecasts - Yahoo Finance

Oct 09, 2026
pulisher
Oct 09, 2026

Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud - GlobeNewswire

Oct 09, 2026
pulisher
Oct 09, 2026

Hims & Hers Health (NYSE: HIMS) Faces Securities Fraud Class Action After FTC Lawsuit Reveal Drives Stock Sharply LowerHBSS - GlobeNewswire Inc.

Oct 09, 2026
pulisher
Oct 09, 2026

Hims & Hers Health climbs 10% amid recent volatile trading (HIMS:NYSE) - Seeking Alpha

Oct 09, 2026
pulisher
Oct 09, 2026

Hims & Hers Health Jumps 7.3% Amid Sector-Wide Rally - AlphaStreet

Oct 09, 2026
pulisher
Oct 09, 2026

HIMS INVESTOR DEADLINE: Hims & Hers Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Before November 2, 2026 Deadline, Robbins Geller Rudman & Dowd LLP Announces - WBOC TV

Oct 09, 2026
pulisher
Oct 08, 2026

ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Hims & Hers Health, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class ActionHIMS - GlobeNewswire Inc.

Oct 08, 2026
pulisher
Oct 08, 2026

Why Hims & Hers Health, Inc. (HIMS) Dipped More Than Broader Market Today - Yahoo Finance

Oct 08, 2026
pulisher
Oct 08, 2026

Reasons to Retain Hims & Hers Stock in Your Portfolio for Now - The Globe and Mail

Oct 08, 2026
pulisher
Oct 08, 2026

Hims & Hers Health Shares Slide as Investors Weigh Accounting Leadership Change and Ongoing Margin Questions - Quiver Quantitative

Oct 08, 2026

Hims Hers Health Inc Stock (HIMS) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Hims Hers Health Inc Stock (HIMS) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Boughton Soleil
Officer
Oct 14 '26
Proposed Sale
29.06
3,461
100,577
0
Okupe Oluyemi
Chief Financial Officer
Oct 01 '26
Sale
29.70
2,000
59,400
234,527
Okupe Oluyemi
Officer
Oct 01 '26
Proposed Sale
29.70
2,000
59,400
0
Boughton Soleil
Chief Legal Officer
Sep 30 '26
Sale
29.17
3,461
100,957
300,809
Boughton Soleil
Officer
Sep 30 '26
Proposed Sale
29.17
3,461
100,957
0
Okupe Oluyemi
Chief Financial Officer
Sep 22 '26
Option Exercise
5.01
14,000
70,140
265,804
Okupe Oluyemi
Officer
Sep 22 '26
Proposed Sale
29.95
29,277
876,846
0
Okupe Oluyemi
Chief Financial Officer
Sep 22 '26
Sale
29.95
29,277
876,846
236,527
Okupe Oluyemi
Chief Financial Officer
Sep 17 '26
Sale
28.82
12,313
354,861
251,804
Okupe Oluyemi
Officer
Sep 17 '26
Proposed Sale
28.82
12,313
354,861
0
$99.70
price down icon 0.29%
$19.18
price down icon 0.36%
$41.22
price up icon 2.79%
$78.59
price down icon 1.69%
RGC RGC
$9.59
price up icon 0.74%
$32.45
price down icon 3.48%
Cap:     |  Volume (24h):